|
rdfs:label
|
"Pertuzumab"@de
"Pertuzumab"@es
"Pertuzumab"@id
"Pertuzumab"@it
"Pertuzumab"@sh
"Pertuzumab"@sr
"Pertuzumabe"@pt
"pertuzumab"@en
"pertuzumab"@fr
"pertuzumab"@nl
"pertuzumab"@pl
"pertuzumab"@sl
"Пертузумаб"@mk
"Пертузумаб"@ru
"Пертузумаб"@uk
"بيرتوزاماب"@ar
"ପର୍ଟୁଜୁମାବ"@or
"ペルツズマブ"@ja
"帕妥珠单抗"@zh
"帕妥珠单抗"@zh-hans
"帕妥珠單抗"@zh-hant
"帕妥珠單抗"@zh-hk
"퍼투주맙"@ko
|
|
skos:altLabel
|
"2C4 Antibody"@en
"MOAB 2C4"@en
"Monoclonal Antibody 2C4"@en
"Omnitarg"@en
"RG-1273"@en
"rhuMAb-2C4"@en
"Перьета"@ru
|
|
schema:description
|
"cheemesch Verbindung"@lb
"chemical compound"@en-ca
"chemical compound"@en-gb
"chemická sloučenina"@cs
"chemická zlúčenina"@sk
"chemiese verbinding"@af
"chemische Verbindung"@de
"chemische Verbindung"@de-ch
"chemische verbinding"@nl
"component quimic"@oc
"compositum chemicum"@la
"compost químic"@ca
"composto químico"@gl
"composto químico"@pt-br
"compuesto quimico"@an
"compuesto químico"@es
"compuestu químicu"@ast
"compus chimic"@ro
"farmaco"@it
"kemia kombinaĵo"@eo
"kemiallinen yhdiste"@fi
"kemisk forbindelse"@da
"kjemisk forbindelse"@nb
"kjemisk sambinding"@nn
"komponim kimik"@sq
"konposatu kimiko"@eu
"medicamento"@pt
"médicament"@fr
"pharmaceutical drug"@en
"senyawa kimia"@id
"związek chemiczny"@pl
"ķīmisks savienojums"@lv
"քիմիական միացություն"@hy
"תרכובת"@he
"مركب كيميائي"@ar
"کیٖمیٲیی مُرَکَب"@ks
"রাসায়নিক যৌগ"@bn
|
|
schema:dateModified
|
"2026-11-04T17:28:35+00:00"^^xsd:dateTime
|
|
schema:version
|
2564773610
|
|
wikibase:identifiers
|
24
|
|
wikibase:sitelinks
|
18
|
|
wikibase:statements
|
40
|
|
p:P10245
|
wd:statement/Q1998021-92444fbc-4312-f433-b619-5823829f2638
|
|
p:P10283
|
wd:statement/Q1998021-731E28D8-4C5F-4BE6-B63B-15012BEABFAF
|
|
p:P10565
|
wd:statement/Q1998021-8edc55b7-48b2-d349-776e-13293cb886c5
|
|
p:P11143
|
wd:statement/Q1998021-98856A6D-7C45-4295-84C0-0688ACD9EF3F
|
|
p:P1269
|
wd:statement/Q1998021-4B189507-09C8-4296-8A60-C352550D9D11
|
|
p:P129
|
wd:statement/Q1998021-40DC239C-8A13-4A10-9F41-13A3B125948E
|
|
p:P14541
|
wd:statement/Q1998021-8683EF76-64C1-49C4-9F7B-1D15F59F4995
|
|
p:P1552
|
wd:statement/Q1998021-1F374CD7-92BE-49BB-B58F-9CD3BFAFCFC1
|
|
p:P2062
|
wd:statement/Q1998021-0D921C1A-CAC2-418B-9717-91A8863FE1F2
|
|
p:P2115
|
wd:statement/Q1998021-4927CFA8-BEF2-4BF3-BB37-D7517D55B24A
|
|
p:P2275
|
wd:statement/Q1998021-62D73BA8-7A75-4978-8694-DFD042270EAF
|
|
p:P231
|
wd:statement/Q1998021-B3962446-D8D2-43FE-8460-CCC63AEF993E
|
|
p:P267
|
wd:statement/Q1998021-10024271-F851-45C4-BF31-CE261DCCB182
|
|
p:P279
|
wd:statement/Q1998021-894d604e-40c0-f703-d2c7-0e998d2f53bc
|
|
p:P2868
|
wd:statement/Q1998021-67300D25-6EB3-414C-8FB3-C8EB035FB304
|
|
wd:statement/Q1998021-78396691-306B-436A-9CCB-A16F874E5D56
|
|
wd:statement/Q1998021-8AB9F150-F0FC-405B-858B-74277545A161
|
|
wd:statement/Q1998021-D8D68275-713A-4089-8896-B1E947F98BB2
|
|
p:P2892
|
wd:statement/Q1998021-b1bbf96d-496a-61c9-df05-b386a7ff04d0
|
|
p:P31
|
wd:statement/Q1998021-CFBC739C-B71E-411B-8BBB-F92C0A61EE2B
|
|
p:P3345
|
wd:statement/Q1998021-3abc2a46-4752-7f3c-0eb6-228b66f251d7
|
|
p:P3350
|
wd:statement/Q1998021-3c7c92c9-49dc-321c-357f-9627133487de
|
|
p:P3489
|
wd:statement/Q1998021-F20F9E05-EA05-4FDD-A892-8B164393FE0A
|
|
p:P3493
|
wd:statement/Q1998021-87377A90-CE50-4D7E-8438-B96C171C0557
|
|
p:P366
|
wd:statement/Q1998021-D7C6BFF2-C4C5-48CC-9D7E-3AB49C2B7247
|
|
p:P373
|
wd:statement/Q1998021-bddbe267-2a6b-4ce4-b91e-cd84de7dffa4
|
|
p:P3780
|
wd:statement/Q1998021-5EF506EF-707B-40DE-8934-2658F9891C03
|
|
p:P4235
|
wd:statement/Q1998021-0B463C94-4DE6-4E38-80CE-DC5CDFAB137D
|
|
p:P4527
|
wd:statement/Q1998021-1BCB28CA-D10A-464A-BDD2-92414F8EB091
|
|
p:P486
|
wd:statement/Q1998021-F904D8D3-476F-4623-B95E-9D11A0ED5F66
|
|
p:P592
|
wd:statement/Q1998021-DB0530B2-8014-4284-ADE3-6B58E897CA4D
|
|
p:P595
|
wd:statement/Q1998021-7bf3fed1-4e55-bb7c-6182-e7ad06fc90fc
|
|
p:P6366
|
wd:statement/Q1998021-E2EC21E9-35D6-4B6A-92DA-1379B7EF9F6F
|
|
p:P646
|
wd:statement/Q1998021-F4B7E86F-F460-4542-BB7A-CAA293BF74D9
|
|
p:P652
|
wd:statement/Q1998021-013AB566-1AFD-479C-B0D4-E9991324CE56
|
|
p:P665
|
wd:statement/Q1998021-DAF044B2-20CB-4C54-AE2E-F6E5D9EE07FE
|
|
p:P715
|
wd:statement/Q1998021-4CCE964A-9949-4606-A06F-6202AC4C57AB
|
|
p:P7524
|
wd:statement/Q1998021-7067EF9D-9E9B-4052-91FC-407418E9A170
|
|
p:P8224
|
wd:statement/Q1998021-BD0D8525-9816-49F3-BD60-1D71B392F78D
|
|
p:P9635
|
wd:statement/Q1998021-8FE55A6C-F8F3-4A5D-8D53-EF87B9C2F0C6
|
|
p:direct-normalized/P2115
|
<http://purl.bioontology.org/ontology/NDFRT/N0000185031>
|
|
p:direct-normalized/P4527
|
<http://data.parliament.uk/terms/434310>
|
|
p:direct-normalized/P486
|
<http://id.nlm.nih.gov/mesh/C485206>
|
|
p:direct-normalized/P592
|
<http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2007641>
|
|
p:direct-normalized/P6366
|
<https://makg.org/entity/2781164504>
|
|
p:direct-normalized/P665
|
<http://www.kegg.jp/entry/D05446>
|
|
wdt:P10245
|
"a612027"
|
|
wdt:P10283
|
"C2781164504"
|
|
wdt:P10565
|
"632924"
|
|
wdt:P11143
|
"Pertuzumab"
|
|
wdt:P1269
|
breast cancer
|
|
wdt:P129
|
Erb-b2 receptor tyrosine kinase 2
|
|
wdt:P14541
|
"3oVUN3"
|
|
wdt:P1552
|
biopharmaceutical
|
|
wdt:P2062
|
"8141"
|
|
wdt:P2115
|
"N0000185031"
|
|
wdt:P2275
|
"pertuzumab"@en
|
|
wdt:P231
|
"380610-27-5"
|
|
wdt:P267
|
"L01XC13"
|
|
wdt:P279
|
protein
|
|
wdt:P2868
|
antineoplastic
|
|
monoclonal antibody
|
|
immunological antineoplastic agent
|
|
developmental toxicant
|
|
wdt:P2892
|
"C1328025"
|
|
wdt:P31
|
type of chemical entity
|
|
wdt:P3345
|
"1298944"
|
|
wdt:P3350
|
"8380"
|
|
wdt:P3489
|
US pregnancy category D
|
|
wdt:P3493
|
boxed warning
|
|
wdt:P366
|
medication
|
|
wdt:P373
|
"Pertuzumab"
|
|
wdt:P3780
|
Perjeta
|
|
wdt:P4235
|
"pertuzumab"
|
|
wdt:P4527
|
"434310"
|
|
wdt:P486
|
"C485206"
|
|
wdt:P592
|
"CHEMBL2007641"
|
|
wdt:P595
|
"5046"
|
|
wdt:P6366
|
"2781164504"
|
|
wdt:P646
|
"/m/027t1rb"
|
|
wdt:P652
|
"K16AIQ8CTM"
|
|
wdt:P665
|
"D05446"
|
|
wdt:P715
|
"DB06366"
|
|
wdt:P7524
|
"pertuzumab"
|
|
wdt:P8224
|
<http://commons.wikimedia.org/wiki/Special:FilePath/Pertuzumab-HER2%20complex%201S78.png>
|
|
wdt:P9635
|
"576"
|